After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline.

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

WASHINGTON, D.C.—FDA Commissioner Martin Makary, M.D., offered more details into the agency’s recently announced plans to ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

RA Ventures, also known as Raven, is a healthcare accelerator for the prominent life sciences venture capital firm. The ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...